Daptomycin Vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Launched by TODD C. LEE MD MPH FIDSA · Oct 9, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective two common antibiotics, vancomycin and daptomycin, are in treating serious bloodstream infections caused by a type of bacteria called methicillin-resistant Staphylococcus aureus (MRSA). The goal is to see which of these medications works better for patients who have this difficult-to-treat infection. The trial is currently looking for participants aged 65 and older who have a confirmed MRSA bloodstream infection. However, individuals who have severe allergies to either of the medications or certain complications, like MRSA pneumonia, may not be eligible to join.
If you or a family member decides to participate in this trial, you will receive one of the two antibiotics as part of your treatment. The trial is open-label, meaning both you and the researchers will know which antibiotic you are receiving. Participants will have regular check-ups to monitor their health and response to the treatment. This study is part of a larger research effort to improve how we treat MRSA infections, and your involvement could help advance medical knowledge and potentially benefit others facing similar health challenges.
Gender
ALL
Eligibility criteria
- The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:
- Inclusion Criteria:
- • Methicillin-resistant S. aureus bacteremia
- Exclusion Criteria:
- • Severe allergy or non-severe rash to vancomycin or daptomycin
- • Suspected or confirmed MRSA pneumonia
- • Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
About Todd C. Lee Md Mph Fidsa
Dr. Todd C. Lee, MD, MPH, FIDSA, is a distinguished clinical trial sponsor with extensive expertise in infectious diseases and public health. With a robust academic background and a commitment to advancing medical research, Dr. Lee leads innovative clinical trials focused on improving patient outcomes and developing novel therapeutic interventions. His multidisciplinary approach combines clinical excellence with strategic insights into epidemiology and healthcare practices, fostering collaborations that drive impactful research initiatives. Dr. Lee's dedication to advancing scientific knowledge and enhancing patient care positions him as a key contributor in the field of clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Surrey, British Columbia, Canada
Patients applied
Trial Officials
Todd C Lee, MD MPH FIDSA
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported